Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from INSPIRE

DST’s decision to scrap KVPY disappoints teachers, aspirants in government schools

The decision of Department of Science and Technology, New Delhi, to scrap Kishore Vaigyanik Protsahan Yojna (KVPY) fellowship from this year has caused disappointment among school teachers who were keenly anticipating its conduct in Tamil for the convenience of the students following the Supreme Court's intervention last year.

Recap Of Tuesday's Biotech Catalysts - End of The Day Summary

Recap Of Tuesday's Biotech Catalysts - End of The Day Summary

European Commission (EC) has approved AbbVie’s (NYSE:ABBV) lead asset RINVOQ (upadacitinib 45 mg [induction dose] and 15 mg and 30 mg [maintenance doses]) for the treatment of adult patients with moderately to severely active ulcerative colitis. AbbVie shares traded in a range of $150.33 to $153.56 on a day volume…

Glasgow residential care group completes shareholder buyout

Glasgow residential care group completes shareholder buyout

ThinCats provides financial backing to Inspire Scotland to complete transaction

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Christian funds in quandary after companies support abortion rights

For money managers who invest billions of dollars in accordance with faith-based teachings, the toppling of the half-century-old US ruling that protected abortion rights was a moment of celebration.

Tribune News Service

Zynerba Pharmaceuticals Reveals Positive Results From Phase 2 INSPIRE Trial Of Zygel In 22q11.2 Deletion Syndrome

Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) revealed positive top line results from the exploratory, open label Phase 2 INSPIRE trial. Based on the positive Phase 2 data, the company will request a meeting with the U.S.

Capricor Shares Fall After Topline Results From Mid-Stage COVID-19 Trial

Capricor Therapeutics Inc (NASDAQ: CAPR) announced topline data from its Phase 2 INSPIRE study evaluating a single-dose intravenous infusion of CAP-1002 for hospitalized COVID-19 patients.

Zynerba Pharmaceuticals Reveals Lower Net Loss For Q4 And Full Year 2021

Manufacturer of transdermal cannabinoid therapies for neuropsychiatric disorders, Zynerba Pharmaceuticals, Inc. Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) reported Tuesday financial results for the fourth quarter and full year ended December 31, 2021.

inkl

Read news from The Economist, FT, and more,
with one subscription

Zynerba Pharmaceuticals Completes Enrollment For CBD Transdermal Trial For 22q Deletion Syndrome

Zynerba Pharmaceuticals Completes Enrollment For CBD Transdermal Trial For 22q Deletion Syndrome

Manufacturer of transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, Zynerba Pharmaceuticals, Inc.

Real-World Analysis Show Takeda's Alofisel Clinical Remission Rate At Six-Months

Real-World Analysis Show Takeda's Alofisel Clinical Remission Rate At Six-Months

Takeda Pharmaceutical Co Ltd (NYSE: TAK) announced the first six-month interim analysis results from INSPIRE study evaluating the Real-World Effectiveness and Safety of Alofisel (darvadstrocel).

INSPIRESat-1 satellite healthy: IIST

INSPIRESat-1 satellite healthy: IIST

It would study ionosphere dynamics and sun's coronal heating processes

IIST has a role in ISRO’s first launch of the year

IIST has a role in ISRO’s first launch of the year

INSPIRESat-1 one of the three satellites to be launched aboard PSLV C-52 tomorrow

Organisations

European Commission

Planned Parenthood

BridgeBio Pharma

Medicines and Healthcare products Regulatory Agency

Global Blood rapeutics

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

Sickle Cell Disease

Ulcerative Colitis

Macular Degeneration

Amyotrophic lateral sclerosis

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

254,562 stories

107,561 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play